Article Details
Retrieved on: 2018-01-01 18:52:30
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
<div>Celgene and Google's GV came back alongside Kleiner Perkins and OrbiMed as well as a broader syndicate including China's <b>Qiming Venture Partners</b> for the C round backing a new technology aimed at whipping up a more potent CD8-positive T cell attack on cancer cells — ground zero in the current ...</div>
Article found on:
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here